UroGen Pharma (URGN) Misses Q1 EPS by 10c

UroGen Pharma (NASDAQ: URGN) reported Q1 EPS of ($0.97), $0.10 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $18.78 million versus the consensus estimate of $21.96 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Broadcom credit risk measures rise amid AI financing deals
• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• MetLife (MET) PT Raised to $106 at Evercore ISI